肺動脈高血圧における血管改造に関与する成長因子
1Department of Physiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan.
Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi
|September 3, 2025
まとめ
血小板由来成長因子 (PDGF) は,肺動脈の滑らかな筋肉細胞の増殖を促進することによって,肺動脈高血圧 (PAH) を誘発する. イマチニブまたはコロソリック酸でPDGFシグナル伝達を抑制すると,ネズミの細胞成長が低下し,血管再構成が改善された.
科学分野:
- 心血管研究
- 肺高血圧の病理学
- 分子生物学
背景:
- 肺動脈高血圧 (PAH) は,肺血管の改造と肺動脈圧 (PAP) の上昇によって特徴づけられる重度の心血管疾患である.
- この再構成には,肺動脈の滑らかな筋肉細胞 (PASMCs) の過剰な増殖と移動が含まれ,これは受容体チロシンキナーゼに結合する成長因子の影響を受けます.
- 以前の研究では,PASMCにおける Ca2+ 感受受容体の高調が,PDGFのレベル上昇と関連したPAHの発症の要因として特定された.
研究 の 目的:
- 肺動脈高血圧 (PAH) の病原性および進行における成長因子,特に血小板由来成長因子 (PDGF) の病理学的役割を検討する.
- 肺血管再構成におけるPASMCのPDGF誘発の増殖と移動の貢献を強調する.
主な方法:
- PAH に関する成長因子に関する既存の文献のレビュー
- PASMCの拡散と移行におけるPDGFとそのシグナル伝達経路の役割の分析
- 肺高血圧の動物モデルにおけるPASMCに対するPDGF阻害剤 (イマチニブ,コロソリック酸) の効果の検討
主要な成果:
- PAH患者におけるPDGF濃度の上昇は,PASMCにおけるCa2+感受受容体を上昇させ,PAHに寄与する.
- イマチニブとコロソリック酸は,PDGFシグナル伝達を抑制することで,過剰なPASMCの増殖と移動を抑制した.
- これらの治療は,肺高血圧のラットモデルにおける肺血管改造を改善する効果を示した.
結論:
- 血小板由来成長因子 (PDGF) は,肺動脈高血圧 (PAH) の発症と進行において重要な役割を果たします.
- PDGFシグナル伝達経路をターゲットにすることで,PASMCの増殖と肺血管の改造を緩和することで,PAHの潜在的な治療戦略を提示します.
関連する概念動画
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Pulmonary Hypertension: Classification and Pathogenesis
284
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
284
Role of Hematopoietic Growth Factors
1.7K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
253
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Mechanism of Angiogenesis
5.8K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.8K


